PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.10%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-94.58%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-14.44%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-14.44%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
4.10%
Interest expense change of 4.10% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.51%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
12.51%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.37%
EPS growth while CRVO declines. John Neff would investigate advantages.
12.37%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.